Functional bowel disease

Cyclooxygenase 2 mediates post-inflammation colonic secretory and barrier dysfunction

S R Zamuner, N Warrier, A G Buret, W K MacNaughton, J L Wallace

Background and aims: The colonic epithelium plays a key role in host defence. During colitis, epithelial function is impaired, leading to elevated bacterial translocation and exacerbation of inflammation. We previously documented perturbation of epithelial function, in terms of secretion and as a barrier to bacterial translocation, that persisted long after resolution of a bout of colitis in the rat. The mechanisms underlying the epithelial dysfunction are not completely understood.

Methods: Given the ability of prostaglandin (PG) D_2 to suppress colonic epithelial secretion, we investigated the potential roles of this eicosanoid and of cyclooxygenase 2 (COX-2) in mediating post-colitis epithelial secretory and barrier dysfunction.

Results: Six weeks after induction of colitis with trinitrobenzene sulphonic acid, there was marked elevated synthesis of PGD_2 and elevated COX-2 expression. Selective COX-2 inhibition abolished the increase in PGD_2 synthesis. Colonic chloride secretory responses (in vitro) were significantly diminished relative to those in controls, a defect that was reversed by pre-exposure to a selective COX-2 inhibitor (celecoxib) but not to a selective COX-1 inhibitor (SC-560). The hyporesponsiveness was mimicked by pre-exposure of normal colonic tissue to PGD_2, but not to its metabolite, 15-deoxy-

Conclusions: These studies demonstrate an important role for COX-2, possibly via generation of PGD_2, in mediating the prolonged epithelial secretory and barrier dysfunction after a bout of colitis in the rat.
Role of COX-2 and PGD2 in epithelial hyporesponsiveness

To examine the role of COX-2 and PGD2 in the hyporesponsiveness of colonic tissue to stimulation by IBMX and EFS, we tested the effects of selective COX-2 (celecoxib 10 μM) and COX-1 (SC-560 300 nM) inhibitors. After mounting in the Ussing chambers, the tissues were exposed to one of these inhibitors or vehicle for 10 minutes prior to stimulation with IBMX or EFS and the short circuit current responses were measured, as above. Celecoxib and SC-560 were initially dissolved in dimethylsulfoxide. The final concentration of dimethylsulfoxide in the Ussing chamber was 0.1%.

Additional studies were performed using colonic tissue from control rats in which the tissue was preincubated with PGD2 (1 μM), the metabolite APGJ3 (1 μM), or vehicle. These prostanoids were initially dissolved in ethanol. The final concentration of ethanol in the Ussing chamber was 0.1%. Isc responses to IBMX and EFS were then measured.

Prostaglandin synthesis and COX-2 expression

Groups of 5–6 rats each were killed on day 1, and one, two, and six weeks after intracolonic TNBS or saline (control) administration. Colonic tissue was collected and processed for measurements of PGE2 and PGD2 as described previously.

Levels of prostaglandins generated by the tissue samples were measured using specific commercially available ELISA kits.

Colonic tissue was also taken from rats killed six weeks after TNBS or saline administration for examination of COX-2 expression by western blotting. Additional groups of rats (control and post-TNBS; n = 6 each) were given lipopolysaccharide (LPS; Escherichia coli serotype 0111:B4) intraperitoneally, and rats were killed six hours later. Tissue samples were taken for assessment of COX-2 expression by western blotting. For all western blot experiments, tissue samples were homogenised in lysis buffer (0.1% Triton X-100, 50 μM peptatin-A, 0.2 mM leupeptin, 1 μg/ml aprotinin, 10 mg/ml phenylmethyl sulphonyl fluoride, 50 mM Tris, and 10 mM EDTA). Samples were then centrifuged and the protein concentration of the supernatant was determined by colorimetric assay (BioRad, Hercules, California, USA). Protein (50 μg) was separated on a 10% polyacrylamide gel and then transferred to a nitrocellulose membrane. The membrane was incubated for one hour with blocking buffer (20 mM Tris, 100 mM NaCl, 0.5% Tween 20, and 5% non-fat dried milk) and then probed overnight with a polyclonal rabbit antibody against COX-2 (1:500; Cayman Chemical, Ann Arbor, Michigan, USA). The membrane was then incubated with a donkey anti-rabbit IgG secondary antibody conjugated to horseradish peroxidase (Amersham, Little Chalfont, UK) for one hour at room temperature. A chemiluminescence reagent (Amersham) was added to visualise the labelling according to the manufacturer’s instructions. Densitometry was done using a GS-710 Calibrated Imaging Densitometer (BioRad) and analysed with Quantity One software (BioRad).

Bacterial translocation and colonic bacterial colonisation

Bacterial translocation and colonic bacterial colonisation in rats six weeks after TNBS administration and in age matched controls were determined as described previously. For bacterial translocation, we examined colonisation of the spleen. As in our previous study, any sample having more than 20 colony forming units (CFU) per gram of tissue was classified as positive for translocation of bacteria. For bacterial colonisation, we measured total numbers of aerobes, as in our previous study we had observed changes in aerobic colonisation and translocation, but not in anaerobic colonisation or translocation. A segment of colon including...
luminal contents was placed in 5 ml of sterile phosphate buffered saline (pH 7.4). The samples were weighed, homogenised, and diluted prior to plating of 0.1 ml of each dilution on blood agar plates. The number of CFU/g tissue was recorded for both control and post-colitis rats. To examine the contribution of COX-2 to any observed changes in bacterial translocation and/or bacterial colonisation, groups of 10–11 rats each were treated twice daily with rofecoxib (3 mg/kg orally) during the sixth week after TNBS administration. A group of control rats (no TNBS; n = 10) was treated with vehicle at the same times. The choice of rofecoxib as a selective COX-2 inhibitor for these in vivo studies, as opposed to celecoxib in the in vitro studies, was entirely based on our having an adequate supply of the former for this multiple dosing study. The dose of rofecoxib was selected based on our previous demonstration that it produced significant inhibition of COX-2 in the rat without affecting COX-1 activity.

Materials
TNBS was obtained from Fluka Chimika (Buchs, Switzerland). IBMX, carbachol, and LPS were purchased from Sigma Chemical Company (St Louis, Missouri, USA). PGD$_2$ and ΔPGJ$_2$ were obtained from Cayman Chemical Company (Ann Arbor, Michigan, USA). Rofecoxib and celecoxib were generous gifts from NicOx (Sophia Antipolis, France), while SC-560 was provided by Boehringer-Ingelheim (Ingelheim, Germany).

Statistical analysis
All data are expressed as mean (SEM). Comparisons among groups of data were made using a one way analysis of variance followed by the Student-Newman-Keuls test. An associated probability (p value) of less than 5% was considered significant.

RESULTS
As in our previous studies,\textsuperscript{a,b} colonic tissue taken from rats six weeks after administration of TNBS did not exhibit any macroscopic or histological signs of damage or inflammation. Colon damage scores in the post-colitis group (1.2 (0.4); n = 14) were not significantly different from those in controls (0.9 (0.2); n = 12). Colonic MPO activity in post-colitis rats (3.9 (0.6) U/mg; n = 14) was not significantly different from that in controls (3.2 (0.4) U/mg; n = 12).

Prostaglandin synthesis and COX-2 expression
Administration of TNBS resulted in a marked increase in colonic synthesis of both PGE$_2$ and PGD$_2$ (fig 1). Synthesis of PGE$_2$ was significantly elevated above basal levels at one day and one week post-TNBS, but had returned to basal levels by two weeks post-TNBS. Changes in PGD$_2$ after TNBS administration followed a very different pattern. There was a significant increase in PGD$_2$ synthesis one day after TNBS, a return towards basal levels at one week, and a second increase in PGD$_2$ synthesis at two weeks that remained evident at six weeks post-TNBS. Thus the greatest increase in PGD$_2$ synthesis was observed during the period when healing of the colonic injury occurred.

To determine the contribution of COX-2 to the elevated synthesis of PGD$_2$ in post-colitis rats, we examined the effects of twice daily treatment with rofecoxib (3 mg/kg orally) during the sixth week post-TNBS on colonic PGD$_2$ synthesis. As shown by the square symbols in fig 1, rofecoxib suppressed colonic PGD$_2$ synthesis to basal levels. These observations therefore suggest that colonic synthesis of PGD$_2$ at six weeks post-TNBS occurred primarily via COX-2.

To further explore the possibility that the elevated colonic PGD$_2$ synthesis was occurring via COX-2, expression of COX-2 in the colon was examined by western blotting. In post-colitis rats, COX-2 was elevated by only 56% above that in controls (p<0.05) (fig 2). However, it was possible that

![Figure 1](http://gut.bmj.com/)

**Figure 1** Colonic synthesis of prostaglandins E$_2$ and D$_2$ at various times after intracolonic administration of trinitrobenzene sulfonic acid (TNBS). PGE$_2$ synthesis was significantly (p<0.05) elevated above basal levels at one day to one week after TNBS administration. PGD$_2$ synthesis was significantly elevated at one day and at two and six weeks post-TNBS. The square symbols show colonic synthesis of PGD$_2$ (filled) and PGE$_2$ (open) in rats treated twice daily during the sixth week post-TNBS with the selective COX-2 inhibitor rofecoxib (3 mg/kg orally). PGD$_2$ synthesis was significantly (p<0.01) reduced by rofecoxib treatment.

![Figure 2](http://gut.bmj.com/)

**Figure 2** Colonic expression of cyclooxygenase 2 (COX-2) in rats six weeks after trinitrobenzene sulfonic acid (TNBS) administration and in age matched controls. Subgroups of rats were treated with lipopolysaccharide (LPS) from *Escherichia coli* six hours prior to the samples being taken. Representative western blots are shown (A). (B) Densitometry data for 5–9 rats per group. *p<0.05 versus the corresponding vehicle (Veh) treated group; **p<0.05 versus the control vehicle treated group.

<table>
<thead>
<tr>
<th>Table 1 Basal short circuit current (µA/cm$^2$) in colonic tissue from control and post-colitis rats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Vehicle</td>
</tr>
<tr>
<td>Celecoxib (10 µM)</td>
</tr>
<tr>
<td>SC-560 (300 nm)</td>
</tr>
<tr>
<td>PGD$_2$ (1 µM)</td>
</tr>
</tbody>
</table>

None of the vehicles used (0.1% dimethylsulphoxide for celecoxib and SC-560, 0.1% ethanol for prostaglandin D$_2$) significantly affected short circuit current (or baseline conductance) and so were pooled for presentation in this table. However, statistical analysis was performed using only data from the appropriate vehicle treated rats. *p<0.05 versus the corresponding vehicle treated group; †p<0.01 versus the corresponding control group (n=3 per group)
COX-2 and post-colitis epithelial dysfunction

COX-2 was “primed” for induction in the post-colitis state. To test this possibility, we administered LPS to control and post-colitis rats, and then measured COX-2 expression. When control rats were given LPS, it caused a small (44%) but significant increase in COX-2 expression in colonic tissue. In contrast, similar stimulation with LPS in the post-colitis group produced a 700% increase in COX-2 expression (fig 2).

**Role of COX-1 and COX-2 in post-colitis epithelial secretory hyporesponsiveness**

Consistent with previous observations of no difference between control and post-colitis colonic tissue in terms of permeability to small molecules, there were no differences between the two groups of rats in terms of conductance, as measured in the Ussing chamber experiments (control: 11.5 (1.2) mS/cm²; post-colitis: 13.6 (1.3) mS/cm²; n = 19 per group). However, the ability of the colonic epithelium of post-colitis rats to secrete was markedly altered compared with controls. As shown in table 1, the basal short circuit current was significantly reduced in post-colitis rats compared with controls. Moreover, as observed in previous studies, the distal colon from rats six weeks after TNBS administration exhibited hyporesponsiveness, in terms of chloride secretion, to both EFS and IBMX (fig 3). Pretreatment of the tissue with SC-560, a selective COX-1 inhibitor, had no effect on the Isc response to either EFS or IBMX in control or post-colitis tissue. In contrast, preincubation of distal colon with celecoxib, a selective COX-2 inhibitor, reversed the hyporesponsiveness seen with both EFS and IBMX (fig 4). There was no significant difference between post-colitis tissue treated with celecoxib and control tissue treated with either

---

**Figure 3** Effects of selective inhibition of cyclooxygenase 1 on changes in colonic short circuit current (Isc) in response to electrical field stimulation (EFS; A) or isobutylmethylxanthine (IBMX; B). Tissues harvested from rats six weeks after induction of colitis (post-colitis) and from age matched controls were studied. The serosal side of the tissues was exposed to SC-560 (300 nM) for 10 minutes prior to stimulation with EFS or IBMX. Values are mean (SEM), with 6–10 rats per group.

**Figure 4** (A) Representative traces of short circuit current recording from colonic tissue mounted in Ussing chambers. The effects of vehicle and of celecoxib (10 µM) are shown in both control and six week post-colitis rats. In each case the tissue was stimulated with isobutylmethylxanthine (IBMX 300 µM), eliciting an increase in the short circuit current. (B, C) Effects of selective inhibition of cyclooxygenase 2 on changes in colonic short circuit current (Isc) in response to electrical field stimulation (EFS; B) or IBMX (C). Tissues harvested from rats six weeks after induction of colitis (post-colitis) and from age matched controls were studied. The serosal side of the tissues was exposed to celecoxib (Celecox 10 µM) for 10 minutes prior to stimulation with EFS or IBMX. Values are mean (SEM), with 6–10 rats per group. *p<0.05 versus the corresponding control group; †p<0.05 versus the corresponding vehicle treated group.
vehicle or celecoxib. Neither celecoxib nor SC-560 significantly affected basal $I_{sc}$ (table 1) or basal conductance (with both drugs basal conductance stayed within the range 10–14 mS/cm², in controls and post-colitis rats).

**Effects of PGD$_2$ and ΔPGJ$_2$ on colonic chloride secretion**

Pre-exposure of distal colon from control rats to PGD$_2$ (1 µM) resulted in ~60% decrease in basal short circuit current (table 1) and a similar decrease in the chloride secretory responses to EFS or IBMX (fig 5). Exposure to PGD$_2$ did not significantly affect conductance (vehicle: 10.1 (1.2) mS/cm²; PGD$_2$: 8.8 (0.8) mS/cm²; $n = 5$ per group). In contrast, pre-exposure of the distal colon to ΔPGJ$_2$ (1 µM), one of the major metabolites of PGD$_2$, did not significantly affect basal $I_{sc}$ or conductance, or the $I_{sc}$ responses to EFS or IBMX (fig 5). Thus acute exposure of normal colonic tissue to PGD$_2$ could mimic the hyporesponsiveness to EFS and IBMX that was observed in colonic tissue from post-colitis rats.

**Effects of COX-2 inhibition on bacterial colonisation and translocation**

Consistent with previous observations, aerobic bacterial colonisation of the distal colon was significantly increased in post-colitis rats compared with age matched controls. In this study, we found that the bacterial counts in the post-colitis group were 12-fold greater than in controls (table 2). Furthermore, there was significantly greater (threecold) translocation of bacteria in the post-colitis group than in controls (table 2). Twice daily treatment with a selective inhibitor of COX-2 (rofecoxib) did not significantly change the numbers of aerobic bacteria in the distal colon of post-colitis rats. However, the incidence of bacterial translocation was reduced from 73% to 18% ($p<0.05$), not significantly different from that observed in control rats (table 1).

**DISCUSSION**

The ability of the gastrointestinal epithelium to act as a barrier is critically important in terms of preventing infection. There are many components to epithelial defence, including the ability of the epithelium to secrete electrolytes, water, and mucus, and the ability (by virtue of tight junctions) to physically restrict the movement of microbes and microbial products into the lamina propria. Impairment of these defensive functions could therefore predispose an organism to bouts of infection and inflammation. Intestinal inflammation has been shown to produce prolonged alterations in smooth muscle function, which could contribute to symptom generation in disorders such as irritable bowel syndrome. In a series of studies over the past few years, we have sought to determine if a bout of inflammation of the intestine would similarly result in prolonged epithelial dysfunction.

In our previous observation that there was a marked increase in bacterial translocation to the spleen in post-colitis rats, we confirmed our previous observation that there was a marked increase in bacterial translocation in the post-colitis rats. Treatment for one week with a selective COX-2 inhibitor reduced bacterial translocation to normal levels. Moreover, the epithelial hyposecretion was mimicked in vitro by PGD$_2$ but not by its metabolite, ΔPGJ$_2$, and was reversed by a selective COX-2 inhibitor, but not a selective COX-1 inhibitor.

PGD$_2$ has been suggested to be important in the resolution of acute inflammation, and it has further been suggested that this prostanoid is primarily derived from COX-2 in this setting. We previously showed that COX-2 derived PGD$_2$ played an important role in downregulating neutrophil infiltration into the mucosa in acute colitis, while Gilroy and colleagues showed an important role of PGD$_2$ and ΔPGJ$_2$, derived from COX-2, in downregulating leucocyte translocation.

---

**Table 2.** Role of cyclooxygenase 2 in elevated colonic bacterial colonisation and translocation following resolution of colitis

<table>
<thead>
<tr>
<th>Group</th>
<th>Total aerobes (log$_{10}$ CFU/g)</th>
<th>Incidence of translocation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control+vehicle</td>
<td>5.40 (0.34)</td>
<td>2/10 (20)</td>
</tr>
<tr>
<td>Post-colitis+vehicle</td>
<td>6.47 (0.31)$^*$</td>
<td>8/11 (73)$^*$</td>
</tr>
<tr>
<td>Post-colitis+rofecoxib</td>
<td>6.05 (0.29)$^*$</td>
<td>2/11 (18)$^*$</td>
</tr>
</tbody>
</table>

Colonic bacterial colonisation and translocation to the spleen were measured six weeks after trinitrobenzenesulphonic acid administration (controls were age matched). Treatment with rofecoxib (3 mg/kg) or vehicle was performed twice daily for the week prior to the rats being killed.

$p<0.05$ versus the control group; $1p<0.05$ versus the post-colitis+vehicle group.
influx in pleuritis. In the present study, we observed marked upregulation of PGD\(_2\) synthesis by the colon during the period of resolution of colitis and healing of colonic ulcers. The increase in PGD\(_2\) synthesis was completely abolished by treatment with rofecoxib, indicating that it was derived primarily from COX-2. A role for COX-2 in the resolution of colitis is also consistent with our previous observation that selective inhibitors of COX-2 exacerbated TNBS-induced colitis in the rat.\(^3\) Surprisingly, the increase in COX-2 expression in post-colitis tissue was only of the order of \(-60\%\) above that in colonic tissue from healthy rats. However, expression of COX-2 appeared to be “primed” in the post-colitis setting as administration of LPS resulted in a much more robust (700\%) increase in expression in post-colitis rats compared with that in healthy controls stimulated with LPS.

PGD\(_2\) has well characterised inhibitory effects on epithelial secretion in the dog and rat.\(^17\)\(^18\) Our observation that PGD\(_2\) reduced IBMX and EFS-stimulated chloride secretion is consistent with previous observations from rat studies.\(^3\)\(^9\) There is some controversy as to which of the two identified PGD\(_2\) receptors mediate the inhibitory effects of PGD\(_2\) on epithelial secretion,\(^4\)\(^6\) and from the results of the present study we cannot shed light on this issue. However, we did observe that \(\Delta\)PGJ\(_2\) did not suppress epithelial secretion when tested at the same concentration as PGD\(_2\). This indicates that the inhibitory effects of PGD\(_2\) did not occur as a consequence of metabolism to \(\Delta\)PGJ\(_2\).

The observed changes in colonic epithelial secretion may have been produced by changes in the epithelium itself, and/ or through changes in several mucosal elements that can influence epithelial function. For example, the enteric nervous system and mucosal stromal and immune cells (for example, myofibroblasts, mast cells) can influence epithelial responses to secretagogues and to EFS. In a previous study,\(^7\) we noted that secretory hyporesponsiveness to EFS, IBMX, and carbachol in tissues from post-colitis rats was not influenced by pre-exposure of the tissues to tetrodotoxin. While this suggests that enteric neurones are not responsible for the post-colitis hyporesponsiveness, one cannot rule out a contribution of tetrodotoxin insensitive nerves, or of other extra-epithelial cells in modulating epithelial function in the post-colitis state. Similarly, the mechanism underlying the prevention of bacterial translocation in post-colitis rats treated with rofecoxib has not been identified. It is possible that normalisation of colonic secretion, as in the in vitro studies demonstrated, resulted in the decrease in bacterial translocation. However, it is also possible that rofecoxib reduced bacterial translocation through other actions on the epithelium or on non-epithelial cells.

In an earlier study, we observed that selective suppression of iNOS could also significantly reduce post-colitis bacterial translocation, and partially reverse secretory hyporesponsiveness.\(^7\)\(^8\) There may be a link between the role of NO production in post-colitis tissue and the observed importance of COX-2. NO derived from iNOS has been reported to mediate the intestinal epithelial hyposecretion in experimental radiation enteritis,\(^4\) and to modulate epithelial barrier function.\(^27\)\(^28\) The latter has been shown to be a direct effect of NO on tight junctions.\(^29\) Thus suppression of NO synthesis would be expected to reverse some of the observed abnormalities in epithelial function in post-colitis rats. However, NO derived from iNOS could also contribute to the COX-2 associated changes in epithelial secretion and barrier function. NO has been shown to stimulate COX activity in a mouse macrophase cell line and in vivo in the rat.\(^30\)\(^31\) Thus increased iNOS can lead to increased COX-2 activity while suppression of iNOS activity results in lower COX-2 activity.\(^30\) Interestingly, iNOS and COX-2 have recently been suggested to mediate alterations in barrier and transport properties of the human intestinal epithelium caused by enteroinvasive bacteria, and these alterations could be partially reversed by inhibitors of either iNOS or COX-2.\(^32\) Moreover, COX-2 has been implicated as a mediator of the smooth muscle dysfunction that persists after a bout of inflammation.\(^33\)

While not the focus of the present study, it is important to note that prolonged elevation of COX-2 has been implicated in proliferative disorders of the large intestine. Also, metabolites of PGD\(_2\) (such as \(\Delta\)PGJ\(_2\)) acting at the PPAR\(\gamma\) receptor, have similarly been implicated as contributing to such disorders.\(^4\) COX-2 appears to play an important role in the pathogenesis of colorectal cancer,\(^4\) the incidence of which is markedly elevated in colitis patients.\(^4\) We observed that COX-2 was “primed” in the post-colitis scenario, such that expression was increased profoundly following stimulation with LPS (relative to healthy controls). Thus we have observed two key alterations that could contribute to proliferative changes in the colon of rats following resolution of colitis, namely, increased bacterial translocation (thus exposure to bacterial endotoxin) and an increased sensitivity to stimulation by bacterial endotoxin in the context of COX-2 expression. The underlying mechanisms for the priming of COX-2 have not yet been identified, and certainly warrant further study.

In summary, the results of the present study further demonstrate the important role the COX-2 derived products in regulating epithelial function. The marked elevation of bacterial translocation in post-colitis rats was reversed by selective inhibition of COX-2, as was epithelial secretory hyporesponsiveness. Whether or not there is a causative link between secretory hyporesponsiveness and impaired barrier function is not yet clear. Colonic secretion of water, which is driven by electrolyte secretion, has been suggested to be very important in mucosal defence, by diluting toxins, flushing away luminal microbes, and delivering secretory IgA.\(^3\) In addition to the potential role of COX-2 in mediating epithelial proliferative changes following colitis, this enzyme and one of its products, PGD\(_2\), appear to contribute significantly to the prolonged alterations in epithelial function that follow a bout of colitis. COX-2 and possibly PGD\(_2\) may therefore represent rational therapeutic targets for preventing these prolonged alterations in epithelial function, which may contribute to the relapses of colonic inflammation that are common in ulcerative colitis and Crohn’s disease.

ACKNOWLEDGMENTS

This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and the National Science and Engineering Research Council. Dr Zamuner is supported by a CIHR/Janssen Pharmaceutica/Canadian Association of Gastroenterology Fellowship. Dr Wallace is an Alberta Heritage Foundation for Medical Research (AHFMR) Scientist and Dr MacNaughton is an AHFMR Senior Scholar.

Authors’ affiliations

S R Zamuner*, N Warrier*, A G Buret, W K MacNaughton, J L Wallace, Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, T2N 4N1, Canada

* S R Zamuner and N Warrier contributed equally to this paper.

REFERENCES


Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction

S R Zamuner, N Warrier, A G Buret, W K MacNaughton and J L Wallace

Gut 2003 52: 1714-1720
doi: 10.1136/gut.52.12.1714

Updated information and services can be found at:
http://gut.bmj.com/content/52/12/1714

These include:

References
This article cites 28 articles, 3 of which you can access for free at:
http://gut.bmj.com/content/52/12/1714#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/